Full history for every metric is available with a Kvantra account
Carmell Therapeutics Corporation (CTCX)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 2 | 2 |
| Operating profit | $m | -7 | -6 | |||||
| Net profit | $m | - | -6 | -9 | -15 | -10 | -7 | -7 |
| EPS reported | $ | -4.83 | -4.71 | |||||
| Operating cashflow per share | $ | -2.33 | -0.99 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -2.34 | -1.00 | |||||
| Free cash flow | $m | -3 | -2 | |||||
| Net debt | $m | -0 | -0 | |||||
| Book value equity | $m | -6 | -9 | |||||
| Book value per share | $ | -4.10 | -3.51 | |||||
| Number of shares | m | 1.43 | 2.48 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.05 | -0.68 | |||||
| P/S LTM | x | 0.15 | 3.52 | |||||
| P/FCF LTM | x | -0.08 | -2.41 | |||||
| EV/EBITDA LTM | x | 0.02 | -1.08 | |||||
| EV/Sales LTM | x | -0.06 | 3.50 | |||||
| Earnings Yield LTM | % | -2448.2% | -1398.1% | |||||
| FCF Yield | % | -1185.4% | -41.45% | |||||
| Quality | ||||||||
| ROE | % | 117.70% | 107.36% | |||||
| ROIC | % | 130.32% | 68.67% | |||||
| Operating margin | % | -371.58% | -343.58% | |||||
| Gross margin | % | 57.23% | 58.98% | |||||
| FCF/Sales | % | -174.79% | -146.06% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +3701.4% | +60.33% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.79 | -9.45 | |||||
| Net Debt/EBITDA | x | 0.06 | -0.04 | |||||
| EBIT/Net interest | x | 390.23 | 520.28 | |||||
| Net debt/market cap | % | -140.68% | -0.60% | |||||
| Net debt/Equity | x | 0.07 | 0.00 | |||||
| Gross debt/equity | x | -0.05 | -0.03 | |||||
Company overview
Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Carmell Therapeutics Corporation (CTCX)
Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free